AI Article Synopsis
- Current treatments, including hypomethylating agents and allogeneic stem cell transplants, show poor outcomes for these patients, with transplants being the only potential cure.
- There is a need for new therapies that can better target TP53 mutations, particularly through direct targeting of the mutant protein and immunotherapies, which show the most promise.
Article Abstract
Mutations in TP53 are observed in ∼20% of patients with myelodysplastic syndromes (MDS), with increased frequency seen in patients with a complex karyotype and cases of therapy-related MDS. TP53 mutations represent perhaps the single greatest negative prognostic indicator in MDS. Inferior outcomes are demonstrated with all approved treatment approaches, although hypomethylating agents remain the standard frontline treatment option. Although outcomes with allogeneic hematopoietic stem cell transplant are poor, it remains the only potentially curative therapy. Novel agents are required to improve outcomes in this molecular subgroup, with therapies that directly target the mutant protein and immunotherapies demonstrating greatest potential.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hoc.2019.11.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!